MSACL 2019 US Abstract

Interpretation of Urine Drug Testing Results for Pain Management

Alec Saitman (1), Frederick Strathmann (2), Deborah French (3), Amadeo Pesce (4)
(1) Providence Regional Laboratories, Portland, OR (2) NMS Laboratories, Willow Grove, PA (3) University of California, San Francisco, San Fransico, CA, (4) University of California, San Diego, San Diego, CA

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Alec Saitman (Presenter) Providence Regional Laboratories

Presenter Bio: Dr. Saitman received his Ph.D. in Organic Chemistry at the University of California, San Diego where he focused his research on the total synthesis of marine natural products. He completed his fellowship training in Clinical Chemistry and Toxicology in the Department of Pathology at the University of California, San Diego under the guidance of Dr. Robert Fitzgerald. Dr. Saitman is double boarded by the American Board of Clinical Chemistry in clinical chemistry and clinical toxicology. He is currently the director of clinical toxicology and special chemistry at Providence Regional Laboratories in Portland Oregon.

Relevant Financial Disclosures (within past 24 months) Committee/Board/Advisory Board Policy and External Affairs Core Committee (PEACC) AACC Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

This session will describe the basics of drug testing interpretation focusing on pain management cases. Quantitative drug testing data derived from mass spectrometry methods do not always provide straightforward answers when evaluating patient compliance. How does one accurately identify patient compliance or non-compliance with data available to the interpreter? This session will help answer that question by first describing the strategies employed by individuals interpreting drug testing results using real world examples. Later, a panel of drug interpretation experts will review actual case studies in real-time to demonstrate the thought process and the tools used to provide accurate interpretations.